VRA Vera Bradley, Inc. gains 36% Mar 22, 2019

Vera Bradley, Inc., together with its subsidiaries, designs, manufactures, and sells women's handbags, luggage and travel items, fashion and home accessories, and gifts. The company offers totes, crossbodies, satchels, clutches, backpacks, baby, and lunch bags; accessories, inclduing wallets, wristlets, eyeglass cases, jewelry, scarves, and various technology accessories; and travel products, such as rolling luggage, cosmetics, and travel and packing accessories, as well as travel bags comprising duffel and weekend bags. It also provides home products consisting of mugs and tumblers, as well as textiles products, such as throw blankets, beach towels, comforters, and wellness and beauty products; offers apparel/footwear, stationery, merchandising, and gift card products; and licenses its products. The company sells its products through two segments, Direct and Indirect. The Direct segment sells Vera Bradley branded products through the company's factory outlet stores in the United States, verabradley.com, and direct-to-consumer eBay sales, as well as through its annual outlet sale in Fort Wayne, Indiana. The Indirect segment offers Vera Bradley branded products to approximately 2,600 specialty retail locations located in the United States, as well as department stores, national accounts, third party e-commerce sites and inventory liquidators, and its wholesale customer in Japan. As of January 28, 2017, the company operated 113 full-line stores and 46 factory outlet stores. Vera Bradley, Inc. was founded in 1982 and is headquartered in Roanoke, Indiana.http://www.priceseries.com/trade/VRA-Vera-Bradley-Inc-stock-gains-36-percent-a-Trade-Record-by-priceSeries-2019021520190322.html

TNDM Tandem Diabetes Care, Inc. gains 58% Mar 22, 2019

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system. In addition, the company offers Tandem Device Updater, a PC and Mac-compatible Web-based system that allows users to update their pump's software; t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:90 and t:30 infusion sets for use with its insulin pump products; and various pump accessories. Its products in development include t:slim X2 with G5 integration; automated insulin delivery systems; t:slim X2 with PLGS; t:slim X2 with TypeZero; and t:sport insulin delivery system. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.http://www.priceseries.com/trade/TNDM-Tandem-Diabetes-Care-Inc-stock-gains-58-percent-a-Trade-Record-by-priceSeries-2019021120190322.html

TGTX TG Therapeutics, Inc. gains 63% Mar 22, 2019

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.http://www.priceseries.com/trade/TGTX-TG-Therapeutics-Inc-stock-gains-63-percent-a-Trade-Record-by-priceSeries-2019020820190322.html

TENX Tenax Therapeutics, Inc. gains 15% Mar 22, 2019

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the development and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company offers Wundecyte, a wound-healing gel. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.http://www.priceseries.com/trade/TENX-Tenax-Therapeutics-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019031420190322.html

RUBI The Rubicon Project, Inc. gains 73% Mar 22, 2019

The Rubicon Project, Inc., a technology company, engages in automating the purchasing and selling of advertising. The company offers advertising automation platform that creates and powers a marketplace for buyers and sellers to readily buy and sell advertising at scale. Its advertising automation platform features applications and services for digital advertising sellers, including Websites, mobile applications, and other digital media properties to sell their advertising inventory; applications and services for buyers comprising advertisers, agencies, agency trading desks, demand side platforms, and ad networks to buy advertising inventory; and a marketplace over which such transactions are executed. The company was founded in 2007 and is headquartered in Los Angeles, California.http://www.priceseries.com/trade/RUBI-The-Rubicon-Project-Inc-stock-gains-73-percent-a-Trade-Record-by-priceSeries-2019010420190322.html

RTIX RTI Surgical, Inc. gains 21% Mar 22, 2019

RTI Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and distributes orthopedic and other surgical implants for use in various surgical procedures worldwide. The company provides natural tissue implants, as well as metal and synthetic implants for the treatment of spinal and other orthopedic disorders. It processes donated human musculoskeletal and other tissues, including bone, cartilage, tendons, ligaments, fascia lata, pericardium, sclera, cornea, and dermal tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company's implants are used in the fields of spine, sports medicine, orthobiologics, bone graft substitutes and general orthopedic, trauma, dental, and surgical specialties. RTI Surgical, Inc. markets its products through its direct distribution force, as well as through a network of independent distributors to hospitals and surgeons. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.http://www.priceseries.com/trade/RTIX-RTI-Surgical-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019022720190322.html

QURE uniQure N.V. gains 72% Mar 22, 2019

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.http://www.priceseries.com/trade/QURE-uniQure-NV-stock-gains-72-percent-a-Trade-Record-by-priceSeries-2019021520190322.html

OLED Universal Display Corporation gains 57% Mar 22, 2019

Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in flat panel displays and solid-state lighting applications. It owns, exclusively licenses, or has the sole right to sublicense approximately 4,200 patents issued and pending worldwide. The company licenses and supplies its proprietary UniversalPHOLED materials to display manufacturers and others. It is also involved in the research, development, and commercialization of other OLED device and manufacturing technologies, including FOLED that are flexible OLEDs for the fabrication of OLEDs on flexible substrates; encapsulation technology for the packaging of flexible OLEDs and other thin-film devices, as well as for use as a barrier film for plastic substrates; UniversalP2OLED, which are printable phosphorescent OLEDs; OVJP, an organic vapor jet printing technology; OVPD, an organic vapor phase deposition for manufacturing a small molecule OLED; and TOLED, which are transparent OLEDs for the fabrication of OLEDs that have transparent cathodes. In addition, the company provides technology development and support services, including government contract work and support provided to third parties for the commercialization of their OLED products. It has strategic relationships with Samsung Display Co., Ltd.; LG Display Co., Ltd.; AU Optronics Corporation; BOE Technology Group Co., Ltd.; Innolux Corporation; Kaneka Corporation; Konica Minolta Holdings Inc.; Lumiotec, Inc.; LG Chem, Ltd.; NEC Lighting, Ltd.; Osram GmbH; Pioneer Corporation; Sony; Sumitomo Chemical Co., Ltd.; and Tianma Micro-electronics Co., Ltd. The company was founded in 1985 and is headquartered in Ewing, New Jersey.http://www.priceseries.com/trade/OLED-Universal-Display-Corporation-stock-gains-57-percent-a-Trade-Record-by-priceSeries-2019012420190322.html

NXST Nexstar Broadcasting Group, Inc. gains 23% Mar 22, 2019

Nexstar Media Group, Inc. operates as a television broadcasting and digital media company in the United States. It focuses on the acquisition, development, and operation of television stations and interactive community Websites in medium-sized markets. The company offers free over-the-air programming to television viewing audiences. It also provides sales, programming, and other services through various local service agreements to 30 power television stations owned and/or operated by independent third parties. As of December 31, 2016, the company owned, operated, programmed, or provided sales and other services to 104 television stations in 62 markets in the states of Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa, Louisiana, Maryland, Michigan, Missouri, Montana, Nevada, New York, North Dakota, Pennsylvania, Tennessee, Texas, Utah, Vermont, Virginia, West Virginia, and Wisconsin. The company's stations reach approximately 20.8 million viewers. The company was formerly known as Nexstar Broadcasting Group, Inc. and changed its name to Nexstar Media Group, Inc. in January 2017. Nexstar Media Group, Inc. was founded in 1996 and is headquartered in Irving, Texas.http://www.priceseries.com/trade/NXST-Nexstar-Broadcasting-Group-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2019021120190322.html

NVTA Invitae Corporation gains 16% Mar 22, 2019

Invitae Corporation, a genetic information company, focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare in the United States, Canada, Israel, and internationally. The company processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics capabilities. It provides a diagnostic service comprising hundreds of genes for various genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas. The company also offers solutions that enable sharing of genetic information consisting of Invitae Family History Tool, an online portal and mobile application that communicates sensitive patient data. In addition, it provides gene sequencing and deletion/duplication analysis; and free re-requisition of additional data within the same indication when ordered, as well as invests in informatics solutions and infrastructure that enable sharing of genetic information to enhance healthcare and clinical outcomes. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.http://www.priceseries.com/trade/NVTA-Invitae-Corporation-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019030720190322.html